Kannalife, Inc. announced that the studies performed on the Company’s patented compound, Atopidine™, suggest that Atopidine™ has outperformed cannabidiol (CBD) in preventing inflammatory responses relevant to UVB-radiation in one of its studies. The Company has conducted scientific comparisons that have been made between two substances: cannabidiol (CBD), a non-psychoactive component of Cannabis, and Atopidine™, a novel, small molecule that has been shown in pre-clinical testing to have protective and anti-inflammatory properties. The inhibition of release of inflammatory substances from skin cells irradiated with UVB-radiation were used to monitor the comparison of the two substances. Although both compounds were effective in preventing the release of TNF-alpha (TNFa), only Atopidine™ was found to be effective in preventing the release of IL-1-beta (IL-1ß) from human epidermal cells. The current experiments suggest that Atopidine™ may be more effective than CBD in preventing inflammatory responses relevant to UVB-radiation.